| Literature DB >> 35299772 |
Sara Soriano-Meseguer1, Elisabet Fuguet1,2, Adriana Port3, Martí Rosés1.
Abstract
In recent years, the parallel artificial membrane permeability assay (PAMPA) has been extended for prediction of skin permeation by developing an artificial membrane which mimics the stratum corneum structure, skin-PAMPA. In the present work, the different parameters affecting skin-PAMPA permeability, such as incubation time and stirring, have been studied to establish ideal assay conditions to generate quality data for a screening of active pharmaceutical ingredients (API) in early stage drug discovery. Another important parameter is membrane retention, which shows dependence on lipophilicity when compounds are in their neutral form. Furthermore, the stability of the membrane has been investigated at different pH values, especially at basic pHs. Finally, a good correlation between human skin permeability and skin-PAMPA permeability, with a large dataset (n = 46), has been established. The optimized assay conditions were an incubation time of 4 hours with stirring in a pH below 8. With all these considerations the thickness of the aqueous boundary layer is decreased as much as possible and the membrane stability is guaranteed.Entities:
Keywords: Membrane retention; Membrane stability; Optimization; Permeation; Skin-PAMPA
Year: 2020 PMID: 35299772 PMCID: PMC8915600 DOI: 10.5599/admet.761
Source DB: PubMed Journal: ADMET DMPK ISSN: 1848-7718
log Pe values of the neutral form of the drugs, obtained from skin-PAMPA assays with and without stirring at different incubation times.
| log | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| With stirring | Without stirring | ||||||||
| Solutes | log | log | p | 30 min | 4 h | 24 h | 30 min | 4 h | 24 h |
| 5-Fluorouracil | -6.82 | -0.89 | 7.86 [ | - | -5.77(±0.02) | -6.16(±0.03) | - | -6.47(±0.22) | -6.07(±0.06) |
| Aminopyrine | -6.55 | 0.80 | 5.00 [ | -5.88(±0.07) | -5.65(±0.01) | -5.17(±0.06) | -5.79(±0.06) | -5.46(±0.06) | -5.22(±0.02) |
| Digitoxin | -8.15 | 2.83 | - | - | -6.42(±0.27) | - | - | -6.34(±0.13) | |
| Flurbiprofen | -4.72 | 4.16 | 4.19 [ | -2.98(±0.13) | -3.69(±0.02) | - | -3.54(±0.06) | -3.85(±0.03) | - |
| Griseofulvin | -6.44 | 2.18 | -5.61(±0.01) | -5.25(±0.10) | -5.12(±0.02) | -5.65(±0.05) | -5.33(±0.07) | -5.20(±0.05) | |
| Hydrocortisone | -7.22 | 1.61 | - | -6.13(±0.03) | -6.04(±0.07) | - | -6.30(±0.18) | -6.14(±0.08) | |
| Ibuprofen | -4.58 | 3.50 | 4.43 [ | -2.71(±0.04) | -3.61(±0.05) | - | -3.59(±0.08) | -3.65(±0.04) | - |
| Naproxen | -4.97 | 3.34 | 4.28 [ | -3.96(±0.12) | -4.19(±0.02) | - | -3.99(±0.08) | -4.24(±0.06) | - |
| Progesterone | -4.90 | 3.87 | -3.25(±0.25) | -4.11(±0.10) | -4.59(±0.15) | -4.81(±0.06) | -4.88(±0.22) | -4.69(±0.12) | |
a From reference [20]
b From reference [19]
c From reference [21]
d From reference [22]
e From reference [23]
Figure 1.Effect of incubation time and stirring in the determination of the skin permeability (log Kp) through the skin-PAMPA permeability (log Pe). Incubation time: 30 minutes (A); 4 hours (B); 24 hours (C); stirred assay (●); non-stirred assay (⨉).
Membrane retention values of the neutral form of the drugs, obtained from skin-PAMPA assays with and without stirring at different incubation times.
|
| |||||||||
|---|---|---|---|---|---|---|---|---|---|
| With stirring | Without stirring | ||||||||
| Solutes | log | log | p | 30 min | 4 h | 24 h | 30 min | 4 h | 24 h |
| 5-Fluorouracil | -6.82 | -0.89 | 7.86 [ | 0.00 | 0.04(±0.04) | 0.08(±0.03) | 0.00 | 0.01(±0.03) | 0.05(±0.02) |
| Aminopyrine | -6.55 | 0.80 | 5.00 [ | 0.00 | 0.00 | 0.05(±0.02) | 0.00 | 0.04(±0.01) | 0.05(±0.02) |
| Digitoxin | -8.15 | 2.83 | 0.00 | 0.22(±0.04) | 0.29(±0.05) | 0.00 | 0.09(±0.03) | 0.25(±0.02) | |
| Flurbiprofen | -4.72 | 4.16 | 4.19 [ | 0.18(±0.03) | 0.00 | 0.00 | 0.13(±0.02) | 0.00 | 0.00 |
| Griseofulvin | -6.44 | 2.18 | 0.06(±0.01) | 0.19(±0.01) | 0.24(±0.02) | 0.03(±0.02) | 0.16(±0.01) | 0.20(±0.02) | |
| Hydrocortisone | -7.22 | 1.61 | 0.02(±0.00) | 0.01(±0.01) | 0.08(±0.03) | 0.00 | 0.04(±0.01) | 0.07(±0.02) | |
| Ibuprofen | -4.58 | 3.50 | 4.43 [ | 0.22(±0.03) | 0.00 | 0.00 | 0.19(±0.07) | 0.09(±0.03) | 0.00 |
| Naproxen | -4.97 | 3.34 | 4.28 [ | 0.13(±0.03) | 0.00 | 0.00 | 0.09(±0.02) | 0.04(±0.02) | 0.00 |
| Progesterone | -4.90 | 3.87 | 0.50(±0.04) | 0.74(±0.01) | 0.88(±0.01) | 0.33(±0.01) | 0.62(±0.04) | 0.83(±0.02) | |
a From reference [20]
b From reference [19]
c From reference [21]
d From reference [22]
e From reference [23]
Figure 2.Relationship between membrane retention (RM) and lipophilicity (log Po/w) at 24 h incubation time without stirring.
Figure 3.Influence of treatment time and pH in skin-PAMPA permeability. Treatment time: 30 minutes (▲); 4 hours (■).
log Kp and log Pe experimental values of the neutral form of the drugs. Both Kp and Pe in cm/s units.
| Solutes | log | log |
|---|---|---|
| 2,4-Dichlorophenol | -4.30 | -3.92± 0.00 |
| 2-Isopropyl-5-Methylphenol (Thymol) | -4.35 | -4.01± 0.00 |
| 2-Nitro-p-phenylenediamine | -6.66 | -5.25±0.02 |
| 3-Methylphenol (m-Cresol) | -4.89 | -4.33±0.01 |
| 4-Amino-2-nitrophenol | -5.91 | -4.59±0.02 |
| 4-Chlorophenol | -4.52 | -4.270.02± |
| 4-Ethylphenol | -4.53 | -4.19±0.02 |
| 4-Hydroxyphenylacetamide | -6.89 | -6.07±0.08 |
| 4-Hydroxy-methylphenylacetate | -5.26 | -5.07±0.09 |
| 4-Nitrophenol | -5.33 | -4.91±0.02 |
| 5-Fluorouracil | -6.82 | -5.77±0.02 |
| 8-Methoxypsoralen | -5.12 | -4.30±0.03 |
| 5,5-Diethylbarbituric acid (Barbital) | -7.29 | -5.75±0.05 |
| 5-Ethyl-5-phenylbarbituric acid (Phenobarbital) | -6.68 | -6.05±0.01 |
| Benzoic acid | -5.68 | -4.82±0.07 |
| 4-Hydroxybenzyl alcohol | -6.26 | -5.85±0.01 |
| Aminopyrine | -6.55 | -5.67±0.03 |
| Aniline | -4.94 | -4.55±0.00 |
| Benzyl nicotinate | -4.87 | -4.16±0.02 |
| Caffeine | -6.85 | -5.45±0.02 |
| Catechol | -5.87 | -5.39±0.00 |
| Cortexolone | -7.20 | -5.45±0.03 |
| Corticosterone | -6.84 | -5.59±0.01 |
| Cortisone | -7.38 | -6.09±0.02 |
| Dexamethasone | -7.27 | -6.25±0.03 |
| Diclofenac | -5.30 | -3.79±0.02 |
| Digitoxin | -8.15 | -6.38±0.15 |
| Estradiol | -5.61 | -4.15±0.07 |
| Fluocinonide | -6.33 | -5.38±0.06 |
| Flurbiprofen | -4.72 | -3.69±0.01 |
| Griseofulvin | -6.44 | -5.28±0.06 |
| Hydrocortisone | -7.22 | -6.17±0.05 |
| Hydroquinone | -6.31 | -5.87±0.06 |
| Hydroxyprogesterone | -6.30 | -4.70±0.05 |
| Ibuprofen | -4.58 | -3.61±0.06 |
| Indomethacine | -5.39 | -4.40±0.04 |
| Isoquinoline | -5.11 | -4.20±0.01 |
| Ketoprofen | -5.22 | -4.68±0.03 |
| Methyl 4-hydroxybenzoate | -5.12 | -4.88±0.04 |
| Methyl phenyl ether (Anisole) | -4.68 | -4.34±0.04 |
| Naproxen | -4.97 | -4.19±0.04 |
| o-Phenylenediamine | -6.70 | -5.42±0.02 |
| Piroxicam | -6.02 | -4.67±0.05 |
| Prednisolone | -7.91 | -6.42±0.02 |
| Progesterone | -4.90 | -4.13±0.02 |
| Testosterone | -5.54 | -4.52±0.03 |
Figure 4.Correlation between human skin permeability and skin-PAMPA permeability.